Cite
A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux.
MLA
Su Hyun Park, et al. “A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 Mg in Patients with Nonerosive Gastroesophageal Reflux.” Gut & Liver, vol. 17, no. 2, Mar. 2023, pp. 226–33. EBSCOhost, https://doi.org/10.5009/gnl220023.
APA
Su Hyun Park, Kang Nyeong Lee, Oh Young Lee, Myung Gyu Choi, Jie-Hyun Kim, In-Kyung Sung, Jae Young Jang, Kyung Sik Park, Hoon Jai Chun, Eun Young Kim, Jun Kyu Lee, Jin Seok Jang, Gwang Ha Kim, Su Jin Hong, Yong Chan Lee, Suck-Chei Choi, Hyun Soo Kim, Tae Oh Kim, Gwang Ho Baik, & Yong Cheol Jeon. (2023). A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux. Gut & Liver, 17(2), 226–233. https://doi.org/10.5009/gnl220023
Chicago
Su Hyun Park, Kang Nyeong Lee, Oh Young Lee, Myung Gyu Choi, Jie-Hyun Kim, In-Kyung Sung, Jae Young Jang, et al. 2023. “A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 Mg in Patients with Nonerosive Gastroesophageal Reflux.” Gut & Liver 17 (2): 226–33. doi:10.5009/gnl220023.